medical benefit

Health insurance company Aetna said that its successful eighth Vitality Re health insurance linked securitisation transaction, the $200 million Vitality Re VIII Ltd. (Series 2017-1), contributes to an enhanced capital position for the firm.

Aetna’s latest and eighth medical benefit claims insurance-linked security (ILS) transaction, Vitality Re VIII Ltd. (Series 2017-1), has now been priced at the low end of coupon guidance, once again reflecting investor demand for these very remote health insurance related risks.

Health insurance giant Aetna has returned to the insurance-linked securities (ILS) market for its eighth Vitality Re transaction, launching a Vitality Re VIII Ltd. (Series 2017-1) deal that seeks $200 million of reinsurance cover against a deterioration of its medical benefit ratio.

Health insurance company Aetna has hailed the completion of its latest ILS transaction, Vitality Re VII Ltd. (Series 2016-1), which it says help it to “reduce its required capital” while gaining a $200m source of collateralized excess of loss reinsurance.

As a result of a piece of health care and health insurance related U.S. legislation named the Consolidated Appropriations Act, 2016 (CAA), signed into law in December, all tranches of Aetna’s Vitality Re V Ltd. and Vitality Re VI Ltd. ILS deals have had their ratings downgraded.

Health insurance firm Aetna’s $200m Vitality Re VII Ltd. (Series 2016-1) health insurance medical benefit ratio catastrophe bond deal has now been priced, with the coupon settling at the upper end of the initial guidance range.

Health insurance firm Aetna is returning to the capital markets in search of another $200 million or more of fully-collateralised reinsurance protection for losses under its health insurance medical benefit ratio, through a Vitality Re VII Ltd. (Series 2016-1) ILS issuance.

Ratings agency Standard & Poor’s has affirmed the ratings of all tranches from three medial benefit ratio or health insurance linked ILS deals sponsored by Aetna. The ratings have been affirmed as S&P said that its rating criteria had previously been misapplied for these deals.

Health care insurance and benefits firm Aetna has hailed the improved “capital efficiency” and reduction in its “weighted average cost of capital” that it has achieved with the successful completion of its sixth medical benefit claims linked Vitality Re VI Ltd. (Series 2015-1) ILS.

Health insurer Aetna’s Vitality Re VI Ltd. (Series 2015-1) ILS has achieved the target size of $200m of protection for the sponsor, while the notes have been priced with one tranche near the lowest end of guidance and the other below it.